Navigation Links
Genetic factors can predict the progression of Parkinson's disease
Date:12/16/2011

Amsterdam, NL -- Parkinson's disease is marked by the abnormal accumulation of α-synuclein and the early loss of dopamine neurons in the substantia nigra region of the brain. A polymorphism in the promotor of α-synuclein gene known as NACP-Rep1 has been implicated as a risk factor for the disease. Now, researchers have found that different variants of NACP-Rep1 and its interaction with the microtubule-associated protein tau (MAPT) H1 haplotype can influence the speed of clinical deterioration in patients with Parkinson's disease.

"Our data are the first to show that polymorphisms of NACP and MAPT interact to influence the rate of progression of Parkinson's disease, a finding with clinical utility," says lead author Yue Huang of Neuroscience Research Australia and the University of New South Wales, Sydney, Australia. "Our study shows that genotypes for NACP and MAPT can be used as a surrogate marker for the estimated rate of Parkinson's disease progression, with positive predictive values of 94-100% for certain genotypes."

123 patients with Parkinson's disease underwent genetic testing to determine NACP-Rep 1 and MAPT H1 allele or genotype. The patient's disease severity was measured using the Unified Parkinson's Disease Rating Scale (UPDRS), and a measurement of disease progression was calculated based on detailed information about disease and symptom onset.

Three common variations, or alleles, of NACP-Rep1 were detected. Patients with one '0' NACP-Rep1 allele had significantly slower disease progression compared to two or no '0' carriers. This may partially reflect the known protective influence of '0' allele on Parkinson's disease. There was a high variation in the estimated rate of disease progression for the '0' allele group due to an interactive effect with the MAPT genotype. The results showed a low relative risk for rapid clinical progression in patients with one NACP-1 '0' allele, or those carrying MAPT non-H1H1 genotype with two NACP-Rep1 '0's. In contrast there was a high risk of a fast clinical progression in patients carrying MAPT H1H1 genotype with two or no NACP-Rep1 '0's.

"Based on current knowledge, it is perhaps not surprising that genetic variation predisposing to high a-synuclein expression gives rise to more rapid progression of PD," notes Dr. Huang. "However, our results suggest that low α-synuclein expression may also be as detrimental in people with high tau expression levels, calling into question the concept that reducing neuronal α-synuclein in all PD patients may be therapeutically advantageous."


'/>"/>
Contact: Daphne Watrin
d.watrin@iospress.nl
31-206-883-355
IOS Press
Source:Eurekalert

Related biology news :

1. Babies born with no eyes: Scientists identify genetic cause
2. Genetics professor Jonathan Arnold named AAAS Fellow
3. Penn geneticists help show bitter taste perception is not just about flavors
4. Video game players advancing genetic research
5. How will patients, families and doctors handle the coming flood of personalized genetic data?
6. Rutgers receives $10 million in support of national efforts to track genetic causes of alcoholism
7. Plant seeds protect their genetic material against dehydration
8. Genetic buzzer-beater genes may save fish
9. Genetic code of first arachnid cracked
10. Cleft lip corrected genetically in mouse model
11. Genetic study confirms: First dogs came from East Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/8/2017)... 7, 2017 Report Highlights The ... from $8.3 billion in 2016 at a compound annual ... Report Includes - An overview of the global ... with data from 2015 and 2016, and projections of ... of the market on the basis of product type, ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... Scientists propose in Nature blocking ... Gaucher and maybe other lysosomal storage diseases as a ... current therapies. An international research team led ... also included investigators from the University of Lübeck in ... 22. The study was conducted in mouse models of ...
(Date:2/22/2017)... Yorba Linda, Ca (PRWEB) , ... February 22, ... ... interactive virtual events for tech innovators, engineers, and scientists from around the world, ... event will place on February 22 and 23, 2017. This premier, online-only conference ...
(Date:2/22/2017)... , Feb. 22, 2017 Origin (Origin Agritech, LLC, a ... and seed provider, and Arcadia (Arcadia Biosciences, ... develops and commercializes agricultural productivity traits and nutritional products, today announced ... biotechnology product developed in China to ... trials. ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma and biotech consulting ... European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins brings ... after more than a decade with leading market research firm, GfK. He began ...
Breaking Biology Technology: